No Data
Guangzhou Kingmed Diagnostics Group (603882) Third Quarter Report Review for 2024: Short-term growth under pressure, significant improvement in cash flow.
Executive summary: performance below expectations, cash flow improvement is evident. Short-term growth is under pressure, with long-term potential for outsourcing penetration rates to increase. Maintaining a shareholding rating. Investment highlights: Maintaining a shareholding rating. Considering the pace of recovery in routine medical examination business and the reduction of credit accounts receivable.
Guangzhou Kingmed Diagnostics Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Guangzhou Kingmed Diagnostics Group (603882): Short-term profit affected by impairment provision, medical resources sinking, and digital transformation continue to accelerate.
Event: The company released its third quarter report for 2024, achieving revenue of 5.619 billion yuan for the first three quarters of 2024, a year-on-year decrease of 10.95%, and achieving a net income attributable to the mother of 0.094 billion yuan, a year-on-year decrease of 83.7%.
Jinyu Medical: Guangzhou Jinyu Medical Testing Group Co., Ltd. 2024 Third Quarter Report
Guangzhou Jinyu Medical Testing Group Co., Ltd. Report for the third quarter of 2024
guangzhou kingmed diagnostics group (603882.SH): the net income in the first three quarters was 93.839 million yuan, a year-on-year decrease of 83.71%.
Gelonghui October 30th | Guangzhou KingMed Diagnostics Group (603882.SH) released its third-quarter report, with revenue for the first three quarters reaching 5.6 billion yuan, a year-on-year decrease of 10.95%. The net income was 93.839 million yuan, down 83.71% year-on-year, with non-GAAP net profit of 78.01 million yuan, down 77.23% year-on-year, and basic earnings per share of 0.20 yuan.
No Data
No Data